


Supplementary information

Additional file 1. Patients and disposition

Countries	Official requests, n	Not approved, n	Withdrawn before approval, n	Approved, n	Withdrawn after approval but before supply, n	Drug supplied, n	Response data, n
Argentina	17	3		14	3	11	6
Australia	83	9		74	9	65	38
Austria	3			3	1	2	2
Belgium	37	3	1	33	1	32	16
Brazil	23			23	8	15	9
Canada	48	6		42	6	36	23
Chile	4			4		4	1
China	1			1		1	
Colombia	2			2		2	1
Costa Rica	1			1		1	1
Czech Republic	1	1					
Denmark	2			2		2	2
Finland	1		1				
France	96	8	2	86	3	83	24
Germany	27	4	1	22	2	20	7
Greece	8			8	2	6	3
Guatemala	1			1	1		
Hong Kong	6			6		6	3
Hungary	2	1		1		1	
Iceland	1	1					

India	2			2		2	1
Ireland	2	1		1		1	1
Israel	13			13	2	11	7
Italy	109	5	2	102	7	95	55
Republic of Korea	4			4		4	2
Lebanon	4			4	2	2	1
Mexico	2			2	1	1	1
The Netherlands	8			8	1	7	3
New Zealand	2			2		2	1
Norway	2	1		1		1	1
Poland	10			10		10	5
Portugal	4			4		4	2
Qatar	1			1		1	
Russian Federation	11			11	1	10	4
Singapore	1			1		1	
Spain	17	3	2	12	2	10	6
Switzerland	7			7	2	5	2
Taiwan	6			6	1	5	3
Turkey	11			11		11	5
United Kingdom	29	2		27	6	21	4
United States	11	3	2	6	3	3	
Total	620	51	11	558	64	494	240

Additional file 2. Summary of requests for avelumab in the expanded access program.

1L, first-line; 2L+, second-line or later.